AI, Medical Products & FDA, Part 2: AI Discovery, Design & Development episode artwork

EPISODE · May 1, 2025 · 43 MIN

AI, Medical Products & FDA, Part 2: AI Discovery, Design & Development

from FDA Watch

In this second part of our AI-focused series in collaboration with Arnold & Porter, Shelly and Wayne chat with Howard Sklamberg, Partner at Arnold & Porter; Eva Temkin, Partner at Arnold & Porter; and Marko Topalovic, Chief AI Officer at Clario, which recently acquired ArtiQ, where he was Founder and CEO. Together, they discuss how AI can accelerate drug discovery and design; how AI could be used in the clinical trial process; how FDA could use AI to evaluate medical product manufacturers' data integrity operations and in inspections; how AI could play a part in product applications; and much more. Access Arnold & Porter's recent AI survey here. This episode and the rest of our series do not include the usual Headlines and Resources Links segments. To subscribe or find out more information about our podcast, visit FDAWatch.net. Want to be a sponsor, marketing partner, or guest, or provide feedback on the podcast? Email us at [email protected].  Music by Dvir Silver from Pixabay.

Episode metadata supplied by the publisher feed · Published May 1, 2025

Embed this episode

NOW PLAYING

AI, Medical Products & FDA, Part 2: AI Discovery, Design & Development

0:00 43:54

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of FDA Watch?

This episode is 43 minutes long.

When was this FDA Watch episode published?

This episode was published on May 1, 2025.

Can I download this FDA Watch episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!